The highly significant superiority after a median follow-up of 19 months with a complete hematological response rate of 95% versus 55%, a complete cytogenetic response rate of 76% versus 15%, an estimated one year 3 log reduction rate of the bcr-abl transcript in 39% versus 2%, and a survival free from progression to accelerated phase or blast crisis of 97% versus 91% (p < 0.001) profoundly changed CML treatment.
← all excerpts
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
1
—
—